Related Experiment Videos
Antigen processing of myelin basic protein is required prior to recognition by T cells inducing EAE
A H Cross1, S Dolich, C S Raine
1Departments of Pathology (Neuropathology), Albert Einstein College of Medicine, Bronx, New York 10461.
Cellular Immunology
|August 1, 1990
Summary
Myelin basic protein (MBP) processing is crucial for activating T cells involved in experimental allergic encephalomyelitis (EAE). Preventing proteolysis during MBP processing maximized T cell proliferation, offering insights into multiple sclerosis.
Area of Science:
- Neuroimmunology
- Molecular immunology
Background:
- Myelin basic protein (MBP) is a key component of central nervous system (CNS) white matter.
- MBP can trigger autoimmune responses, leading to experimental allergic encephalomyelitis (EAE) in animal models.
- EAE serves as a primary animal model for studying human inflammatory CNS demyelinating conditions like multiple sclerosis.
Purpose of the Study:
- To investigate the processing and presentation requirements of whole MBP and an encephalitogenic peptide.
- To understand the activation mechanisms of MBP-specific T cells in the context of EAE.
Main Methods:
- Utilized MBP-immune and peptide-immune murine T cell lines.
- Administered MBP-immune T cell lines to induce adoptively transferred EAE in naive recipients.
- Assessed T cell proliferation in response to processed and unprocessed MBP and peptide.
Main Results:
- Both whole MBP and the peptide required processing to induce T cell line proliferation.
- Maximal T cell proliferative response occurred when MBP was processed under conditions inhibiting proteolysis.
- MBP-immune T cell lines successfully induced a form of EAE upon adoptive transfer.
Conclusions:
- Activation of encephalitogenic MBP-immune T cells necessitates a processed form of MBP.
- The requirement for processed MBP in T cell activation has potential implications for understanding and treating multiple sclerosis.
- Understanding MBP processing in EAE may reveal therapeutic targets for human demyelinating diseases.